Search Results

By Matthew Stenger  / Thursday, January 22, 2015 12:25 PM

No Survival Benefit of Adding Erlotinib to Sorafenib in Advanced Hepatocelluar Carcinoma

In the phase III SEARCH trial reported in the Journal of Clinical Oncology, Zhu et al found no overall survival benefit of adding erlotinib (Tarceva) to sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma. Study Details In this double-blind trial conducted in 26 countries in...